Tirzepatide
TR10 · 10mg · 2026-10-21 · N/A
COA PDF ↗
TR20Images are illustrative. Actual specifications are as selected and confirmed in writing.
GLP-1 & Metabolic Research
Tirzepatide
Weight reduction, maintenance, body composition and direct comparisons
Tirzepatide specifications and reference prices. Select a specification to add it to your cart.
20mg/vial x 10vials
Reference priceUS$160.61
For laboratory research only. Not for human or veterinary use.
COA 检测报告 / Reports
Compare all specifications & reference prices
| SKU | Specification / pack | Reference price (USD) |
|---|---|---|
| TR5 | 5mg/vial x 10vials | US$57.58 |
| TR10 | 10mg/vial x 10vials | US$96.97 |
| TR15 | 15mg/vial x 10vials | US$127.27 |
| TR20 | 20mg/vial x 10vials | US$160.61 |
| TR30 | 30mg/vial x 10vials | US$206.06 |
| TR40 | 40mg/vial x 10vials | US$290.91 |
| TR50 | 50mg/vial x 10vials | US$333.33 |
| TR60 | 60mg/vial x 10vials | US$460.61 |
| TR100 | 100mg/vial x 10vials | US$575.76 |
| TR120 | 120mg/vial x 10vials | US$636.36 |
Temporarily sold-out specifications can still be added to an inquiry to ask about restocking. An inquiry is not an order or an agreed price.
DOCUMENTATION / TR20
Tirzepatide — supplied COA and inquiry notes
The Tirzepatide catalog group currently lists 10 specifications. Use the selector and specification table above to compare SKUs and reference prices. The linked report identifies sample TR20; its sample code is not a separate specification selection.
- Report sample code
- TR20
- Reported date
- 2026-08-16
- Sample purity (HPLC-UV)
- 99.72%
- Sample net content
- 22.04 mg
- Lot / batch field
- N/A
- Endotoxin result
- N/A
These values describe the supplied test sample only.
When inquiring about Tirzepatide, include the exact SKU, pack quantity and destination. Ask for stock and batch-document confirmation. Temporarily sold-out specifications can still be queried; the cart is not a confirmed order.
For laboratory research only. Not for human or veterinary use. The supplied report footnotes also exclude diagnostic, therapeutic and clinical applications.
Explore GLP-1 & Metabolic Research ↗ · View all products
RESEARCH FOCUS
Main Uses & FAQs
This page brings together research directly related to weight reduction, maintenance, body composition and direct comparisons involving Tirzepatide. Start with the research questions and findings, then check the study populations or species, formulations and scope of interpretation.
Main TopicsWeight Reduction · Maintenance · Body Composition · Direct Comparison
USAGE REFERENCE
Tirzepatide · Usage Reference (Research Use)
The following presents common research-context references for reconstitution, storage, dosage and cycles. The following presents common references in research settings. This page does not constitute advice for use in humans or animals.
🧪Reconstitution
- Suggested Diluent
- Bacteriostatic Water (containing 0.9% benzyl alcohol); some peptides may use sterile water or acetic acid to aid dissolution. See the individual product descriptions.
- Diluent Volume
- Slowly introduce the diluent along the vial wall until the lyophilized powder is covered. A common example is 5 mg reconstituted with 2 mL of bacteriostatic water, yielding approximately 2.5 mg/mL. Referenced reconstitution volumes are approximately 1–2.5 mL, with 2 mL commonly used. It is suggested to select and record a fixed volume based on the COA supplied with the purchase.
- Handling Notes
- Introduce the diluent slowly along the vial wall rather than directly onto the lyophilized powder. Leave it for 60–90 seconds to dissolve naturally; do not shake vigorously.
💾Storage
- Unreconstituted Lyophilized Powder
- Refrigerate at 2–8°C, protected from light; avoid repeated freeze–thaw cycles.
- After Reconstitution
- Refrigerate at 2–8°C; a common recommendation is touse within 28 days; do not freeze.
- Transport
- For short periods, use insulated packaging with ice packs; avoid high temperatures and direct light.
📏Dosage Reference (Research)
| Purpose / Setting | Common Reference |
|---|---|
| Administration Route | Subcutaneous injection (rotating abdominal / thigh sites) |
| Frequency | Once weekly |
🔁Cycle
Once weeklyat a consistent time, rotating injection sites.
View the Complete Usage Guide Library →Note: The above describes common research-context references, rather than clinical recommendations. Refer to the batch COA and research protocol. For research use only; not for human or animal use.
References
Read the Full Research Review ↗Research SummaryKey Findings
What has Tirzepatide research found about weight reduction, maintenance, body composition and direct comparisons?
Continued study treatment maintained prior weight reduction better than switching to placebo, supporting research into long-term weight management. Another study reported mean weight changes of −20.2% with tirzepatide and −13.7% with semaglutide, with greater reductions in weight and waist circumference in the former group.[1] ↗ [2] ↗
Before ReadingStudy populations, species, formulations and delivery conditions each have a defined scope. Research on an ingredient does not establish that this site's product batches have been validated for efficacy in humans or veterinary use.
Human Study2026REF. 01
How Can Long-Term Weight Reduction Be Maintained?
Research Findings
Continued treatment was more effective than switching to placebo in maintaining previous weight loss, supporting long-term weight management research.[1] ↗
Study Design
Adult obesity; after 60 weeks of open weight loss, 378 people entered a 52-week randomized maintenance phase
Scope & Limitations
Selects populations who completed the importation period; there are remedial treatments and different estimated targets. Attached is the correction for PMID42242249; numerical values need to be checked against the corrected original text; does not directly provide individual dose reduction plans.
View the Article Title and Full Citation＋
Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial.
Lancet (London, England) · Volume, issue, year 2026
First published 2026-05-12 · PMID 42119587
DOI 10.1016/S0140-6736(26)00656-2
Attached journal correction:PMID 42242249 ↗; this page does not cite the precise weight loss numbers in the paper that are yet to be verified.
Human Study2025REF. 02
How Did Weight Reduction Compare with Semaglutide?
Research Findings
Average weight change: Terbipetide −20.2%, Semaglutide −13.7%; the former shows greater weight and waist reduction.[2] ↗
Study Design
SURMOUNT-5; 751 adults with obesity without type 2 diabetes; 72-week randomized open-label controlled trial
Scope & Limitations
Limited to this trial population, maximum tolerated study dose, and 72-week conditions; common adverse events are gastrointestinal responses. Study drug is not equivalent to the research product on this site.
View the Article Title and Full Citation＋
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
The New England Journal of Medicine · Volume, Issue, Year 2025
First published 2025-05-11 · PMID 40353578
DOI 10.1056/NEJMoa2416394
Human Study2025REF. 03
Did Weight Reduction Mainly Come from Fat?
Research Findings
The Terebopetide group showed greater reductions in weight and fat mass than placebo; about 75% of weight loss in both groups came from fat mass.[3] ↗
Study Design
SURMOUNT-1 DXA sub-study; 160 people, 72 weeks
Scope & Limitations
About 25% of weight loss comes from lean body mass and cannot be marketed as fat-only loss without muscle loss; it is a sub-study of the parent trial, not an independent replication.
View the Article Title and Full Citation＋
Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.
Diabetes, obesity & metabolism · Volume and Issue Year 2025
First published 2025-02-25 · PMID 39996356
DOI 10.1111/dom.16275
Human Study2025REF. 04
Can Weight Reduction Persist for Three Years?
Research Findings
The study shows average weight loss across dosage groups of 12.3%–19.7%, placebo 1.3%, supporting long-term weight management.[4] ↗
Study Design
SURMOUNT-1; 1,032 people with obesity and prediabetes; 176-week randomized study
Scope & Limitations
Limited to obese populations with prediabetes; shares parent trial with DXA paper; common gastrointestinal adverse events should be understood in context of the original text.
View the Article Title and Full Citation＋
Tirzepatide for Obesity Treatment and Diabetes Prevention.
The New England Journal of Medicine · Volume, Issue, Year 2025
First published 2024-11-13 · PMID 39536238
DOI 10.1056/NEJMoa2410819
Human Study2024REF. 05
What Does Continued Treatment Mean for Weight-Loss Maintenance?
Research Findings
Among continued treatment participants, 89.5% maintained at least 80% of induction-phase weight loss, compared to 16.6% of those switched to placebo, supporting weight maintenance studies.[5] ↗
Study Design
SURMOUNT-4; 670 people randomized for 52 weeks after a 36-week lead-in
Scope & Limitations
To complete the import phase in a specific population; changes after randomization cannot be confused with changes from week 0; not personal medication advice.
View the Article Title and Full Citation＋
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
JAMA · Volume/Issue/Year 2024
First published 2024-01-02 · PMID 38078870
DOI 10.1001/jama.2023.24945
Five original studies related to this page's topic are currently selected. They include different designs, populations or formulations; the number of papers is not a clinical efficacy rating for the product. This page is a use-oriented selection of positive research materials, rather than a systematic review or administration advice. Historical research, combination formulations and specialized models are identified separately.
GO DEEPER
↗What Questions Do These Studies Address?
Compare study populations, findings and scope.
Tirzepatide · FAQs
What has Tirzepatide research found about weight reduction, maintenance, body composition and direct comparisons?＋
Continued study treatment maintained prior weight reduction better than switching to placebo, supporting research into long-term weight management. Another study reported mean weight changes of −20.2% with tirzepatide and −13.7% with semaglutide, with greater reductions in weight and waist circumference in the former group.[1] ↗ [2] ↗
Does all the weight lost come from fat?＋
No. In the DXA substudy, approximately 75% of weight loss came from fat mass and approximately 25% from lean mass. Lean mass is not the same as muscle alone, so this cannot be described as 'losing only fat without losing muscle.'[3] ↗
Which study populations do these Tirzepatide findings apply to?＋
Adult obesity; after 60 weeks of open weight loss, 378 people entered a 52-week randomized maintenance phase; SURMOUNT-5; 751 obese adults without type 2 diabetes; 72-week randomized open control; SURMOUNT-1 DXA sub-study; 160 people, 72 weeks. Selecting people who completed the induction phase; remedial treatment and different estimation targets exist. Corrected PMID42242249 attached, values must be verified with the original corrected text; does not directly provide individual reduction plans.[1] ↗ [2] ↗ [3] ↗
VENTRO PEPTIDES & BIOTECH · RESEARCH PRODUCT RETAIL
Research peptides. Shop by product.
Compare specifications, reference prices and COA reports. Add products to your cart to request a quote.
QUALITY DOCUMENTSCOA BY PRODUCTGLOBAL DELIVERYTECHNICAL SUPPORT
01 / CATALOG
Browse products
Images are illustrative. Actual specifications are as selected and confirmed in writing.
GLP-1 & Metabolic Research
Semaglutide
10mg/vial x 10vials
US$90.91Images are illustrative. Actual specifications are as selected and confirmed in writing.
GLP-1 & Metabolic Research
Tirzepatide
20mg/vial x 10vials
US$160.61
Images are illustrative. Actual specifications are as selected and confirmed in writing.
GLP-1 & Metabolic Research
Retatrutide
10mg/vial x 10vials
US$109.09
Images are illustrative. Actual specifications are as selected and confirmed in writing.
Repair & Recovery Research
BPC157
10mg/vial x 10vials
US$133.33
Images are illustrative. Actual specifications are as selected and confirmed in writing.
Longevity & Mitochondrial Research
MOTS-C
20mg/vial x 10vials
US$257.58
Images are illustrative. Actual specifications are as selected and confirmed in writing.
GLP-1 & Metabolic Research
Liraglutide
10mg*10vials
US$164.71
Images are illustrative. Actual specifications are as selected and confirmed in writing.
Growth Hormone & IGF-1
IGF-lr3
1mg/vial x 10vials
US$505.8802 / DISCOVER
Browse categories
01 / 04
03 / ABOUT VENTRO
Reliable peptide supply, built for long-term partnerships.
Ventro supports research product retail purchases with clear pack specifications, available quality documents, and responsive international support.
- High-purity peptides
- Available COA reports
- COA & quality documentation
- Flexible small-quantity purchases
- Reliable global fulfillment
- Research product retail support
04 / QUALITY SYSTEM
Quality without compromise
Browse the available COA reports by product. Confirm documentation for your order with our team.
Controlled quality workflowRaw material to final release
Responsive global supportProduct matching and technical support
RESEARCH PRODUCT INQUIRY
Submit a product inquiry
Tell us the product, specification, and expected quantity. Our team will respond with pricing and available documents.